[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, blocking the transfer of cholesteryl esters from HDL to LDL particles, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 12.4, "open": 12.54, "dayLow": 12.54, "dayHigh": 12.54, "regularMarketPreviousClose": 12.4, "regularMarketOpen": 12.54, "regularMarketDayLow": 12.54, "regularMarketDayHigh": 12.54, "beta": -0.035, "volume": 554, "regularMarketVolume": 554, "averageVolume": 2405, "averageVolume10days": 3350, "averageDailyVolume10Day": 3350, "bid": 12.01, "ask": 0.0, "bidSize": 1, "askSize": 0, "fiftyTwoWeekLow": 5.52, "fiftyTwoWeekHigh": 16.75, "fiftyDayAverage": 11.17692, "twoHundredDayAverage": 9.61627, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 53942509, "bookValue": 7.01, "priceToBook": 1.788873, "netIncomeToCommon": -241598000, "52WeekChange": 0.12799263, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 12.54, "recommendationKey": "none", "totalCash": 834190016, "totalCashPerShare": 7.596, "ebitda": -176176000, "totalDebt": 448000, "quickRatio": 8.001, "currentRatio": 8.075, "totalRevenue": 45563000, "debtToEquity": 0.059, "revenuePerShare": 0.483, "returnOnAssets": -0.18186001, "returnOnEquity": -0.46199, "grossProfits": 45563000, "freeCashflow": -43394624, "operatingCashflow": -158564000, "revenueGrowth": 14.905, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -3.38467, "financialCurrency": "USD", "symbol": "NAMSW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "marketState": "REGULAR", "regularMarketChangePercent": 1.1290351, "regularMarketPrice": 12.54, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612967400000, "regularMarketChange": 0.14000034, "regularMarketDayRange": "12.54 - 12.54", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2405, "fiftyTwoWeekLowChange": 7.02, "fiftyTwoWeekLowChangePercent": 1.2717391, "fiftyTwoWeekRange": "5.52 - 16.75", "fiftyTwoWeekHighChange": -4.21, "fiftyTwoWeekHighChangePercent": -0.25134328, "fiftyTwoWeekChangePercent": 12.799263, "fiftyDayAverageChange": 1.36308, "fiftyDayAverageChangePercent": 0.12195489, "twoHundredDayAverageChange": 2.92373, "twoHundredDayAverageChangePercent": 0.30403993, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-03-18", "cryptoTradeable": false, "corporateActions": [], "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketTime": 1742399950, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]